"Increase, increased" References in the ICD-10-CM Index to Diseases and Injuries
- Increase, increased
- abnormal, in development - R63.8 Other symptoms and signs concerning food and fluid intake
- androgens (ovarian) - E28.1 Androgen excess
- anticoagulants (antithrombin) (anti-VIIIa) (anti-IXa) (anti-Xa) (anti-XIa) - See: Circulating anticoagulants;
- cold sense - R20.8 Other disturbances of skin sensation
- estrogen - E28.0 Estrogen excess
- heat sense - R20.8 Other disturbances of skin sensation
- intracranial pressure (benign) - G93.2 Benign intracranial hypertension
- permeability, capillaries - I78.8 Other diseases of capillaries
- pressure, intracranial - G93.2 Benign intracranial hypertension
- gastrin - E16.4 Increased secretion of gastrin
- glucagon - E16.3 Increased secretion of glucagon
- pancreas, endocrine - E16.9 Disorder of pancreatic internal secretion, unspecified
- growth hormone-releasing hormone - E16.8 Other specified disorders of pancreatic internal secretion
- pancreatic polypeptide - E16.8 Other specified disorders of pancreatic internal secretion
- somatostatin - E16.8 Other specified disorders of pancreatic internal secretion
- vasoactive-intestinal polypeptide - E16.8 Other specified disorders of pancreatic internal secretion
- sphericity, lens - Q12.4 Spherophakia
- splenic activity - D73.1 Hypersplenism
- venous pressure - I87.8 Other specified disorders of veins
- portal - K76.6 Portal hypertension
Applicable Clinical Terms Definitions
Estrogens: Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds.
Gastrins: A family of gastrointestinal peptide hormones that excite the secretion of GASTRIC JUICE. They may also occur in the central nervous system where they are presumed to be neurotransmitters.
Glucagon: A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511)
Pancreatic Polypeptide: A 36-amino acid pancreatic hormone that is secreted mainly by endocrine cells found at the periphery of the ISLETS OF LANGERHANS and adjacent to cells containing SOMATOSTATIN and GLUCAGON. Pancreatic polypeptide (PP), when administered peripherally, can suppress gastric secretion, gastric emptying, pancreatic enzyme secretion, and appetite. A lack of pancreatic polypeptide (PP) has been associated with OBESITY in rats and mice.
Bodily Secretions: Endogenous substances produced through the activity of intact cells of glands, tissues, or organs.
Somatostatin: A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.
Venous Pressure: The blood pressure in the VEINS. It is usually measured to assess the filling PRESSURE to the HEART VENTRICLE.